SG11202001368SA - Antigen-binding proteins tatrgeting shared antigens - Google Patents

Antigen-binding proteins tatrgeting shared antigens

Info

Publication number
SG11202001368SA
SG11202001368SA SG11202001368SA SG11202001368SA SG11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA
Authority
SG
Singapore
Prior art keywords
tatrgeting
antigen
binding proteins
shared antigens
antigens
Prior art date
Application number
SG11202001368SA
Inventor
Karin Jooss
Wade Blair
Brendan Bulik-Sullivan
Jennifer Busby
Michele Anne Busby
Mojca Skoberne
Roman Yelensky
Joshua Francis
Gijsbert Grotenbreg
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of SG11202001368SA publication Critical patent/SG11202001368SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
SG11202001368SA 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens SG11202001368SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547146P 2017-08-18 2017-08-18
US201762581368P 2017-11-03 2017-11-03
PCT/US2018/046997 WO2019036688A1 (en) 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens

Publications (1)

Publication Number Publication Date
SG11202001368SA true SG11202001368SA (en) 2020-03-30

Family

ID=65362959

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001368SA SG11202001368SA (en) 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens

Country Status (12)

Country Link
US (2) US20210147550A1 (en)
EP (1) EP3668539A4 (en)
JP (1) JP2021500852A (en)
KR (1) KR20200084320A (en)
CN (1) CN111328288A (en)
AU (1) AU2018318303A1 (en)
CA (1) CA3072816A1 (en)
IL (1) IL272466A (en)
MX (1) MX2020001879A (en)
SG (1) SG11202001368SA (en)
WO (1) WO2019036688A1 (en)
ZA (1) ZA202001285B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3616706T (en) 2014-12-23 2021-11-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019133853A1 (en) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
KR20210003767A (en) * 2018-04-19 2021-01-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T cell receptor with MAGE-B2 specificity and uses thereof
CN111138521B (en) * 2018-11-06 2022-10-28 香雪生命科学技术（广东）有限公司 Short peptides derived from AFP antigen
CN111138522B (en) * 2018-11-06 2023-01-24 香雪生命科学技术（广东）有限公司 Tumor antigen short peptides derived from AFP
EP3941491A4 (en) 2019-03-21 2023-03-29 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
WO2020227091A1 (en) * 2019-05-03 2020-11-12 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
KR20220052910A (en) * 2019-07-09 2022-04-28 메디진 이뮤노테라피스 게엠바하 MAG10 specific T cell receptor and uses thereof
KR20220047277A (en) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 HIV Vaccines, and Methods of Making and Using the Same
CN112300261B (en) * 2019-07-23 2023-03-17 香雪生命科学技术（广东）有限公司 Tumor antigen short peptide derived from AFP
US20210206856A1 (en) * 2019-08-19 2021-07-08 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
WO2021048381A1 (en) * 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
EP4045066A4 (en) * 2019-10-18 2024-03-20 Univ Texas Hla-restricted vcx/y peptides and t cell receptors and use thereof
WO2021092094A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
IL292535A (en) * 2019-11-15 2022-06-01 Gritstone Bio Inc Antigen-binding proteins targeting shared neoantigens
CN112898399A (en) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 Short peptides derived from AFP antigens
CN115960205A (en) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 Thymus-dependent lymphocyte antigen epitope peptide of primary liver cancer-related antigen and application thereof
CN113072636A (en) * 2020-01-06 2021-07-06 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP and its code sequence
CN113321727B (en) * 2020-02-28 2024-04-09 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP antigen short peptide and coding sequence thereof
CN113321725A (en) * 2020-02-28 2021-08-31 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP
CN115485295A (en) * 2020-03-10 2022-12-16 麻省理工学院 Compositions and methods for immunotherapy of NPM1 c-positive cancers
CN113493505A (en) * 2020-03-20 2021-10-12 香雪生命科学技术（广东）有限公司 High affinity TCR recognizing AFP antigen
JP2023527293A (en) * 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド MAGEB2 binding construct
CN114730938A (en) 2020-07-08 2022-07-08 株式会社Lg新能源 Battery pack and vehicle including the same
WO2022026772A1 (en) * 2020-07-29 2022-02-03 Gritstone Bio, Inc. Engineered multi-specific antibodies and related methods of use and manufacture
GB2614166A (en) * 2020-09-04 2023-06-28 Us Health T cell receptors recognizing R273C or Y220C mutations in P53
CA3194664A1 (en) * 2020-10-23 2022-04-28 Xi Chen Compositions and methods for t-cell receptor identification
EP4240377A1 (en) * 2020-11-05 2023-09-13 Board of Regents, The University of Texas System Engineered t cell receptors targeting egfr antigens and methods of use
EP4277925A1 (en) * 2021-01-14 2023-11-22 Gritstone bio, Inc. Multi-specific antibodies and methods of use
EP4294831A1 (en) * 2021-02-16 2023-12-27 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against cd22
WO2022190009A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
JP2024514477A (en) * 2021-03-29 2024-04-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム SARS-COV-2 ANTIGEN-TARGETING PEPTIDES AND ENGINEERED T-CELL RECEPTORS AND METHODS OF USE
EP4329780A1 (en) 2021-04-29 2024-03-06 Yeda Research and Development Co. Ltd T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
KR20240045239A (en) * 2021-08-06 2024-04-05 안야디, 엘엘씨 Manufacturing method of personalized cancer immunotherapy
WO2023050063A1 (en) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 Tcr recognizing hla-a*02:01/e629-38, and application thereof
WO2023077100A1 (en) * 2021-10-29 2023-05-04 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023164455A2 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods to modulate the immune system
NL2031118B1 (en) * 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
CN116836261A (en) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 High-affinity TCR (TCR) for recognizing MAGE-A4 antigen, and sequence and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
EP1485075A4 (en) * 2002-02-20 2006-04-26 Dyax Corp Mhc-peptide complex binding ligands
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP3392270B1 (en) * 2011-09-15 2020-08-26 The United States of America, as Represented by the Secretary Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
US20150018530A1 (en) * 2012-02-29 2015-01-15 Ambrx, Inc. Novel Prodrug Containing Molecule Compositions and Their Uses
TWI701258B (en) * 2014-12-19 2020-08-11 美商再生元醫藥公司 Human antibodies to influenza hemagglutinin
WO2016191246A2 (en) * 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide
GB201520559D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN109069627A (en) * 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 To the T cell receptor sample antibody of the derivative peptide specific of FOXP3

Also Published As

Publication number Publication date
ZA202001285B (en) 2021-08-25
US20230382997A1 (en) 2023-11-30
KR20200084320A (en) 2020-07-10
AU2018318303A1 (en) 2020-04-09
EP3668539A4 (en) 2021-08-18
EP3668539A1 (en) 2020-06-24
CN111328288A (en) 2020-06-23
IL272466A (en) 2020-03-31
WO2019036688A1 (en) 2019-02-21
US20210147550A1 (en) 2021-05-20
JP2021500852A (en) 2021-01-14
CA3072816A1 (en) 2019-02-21
MX2020001879A (en) 2020-07-29

Similar Documents

Publication Publication Date Title
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
IL275547A (en) Antigen-binding proteins targeting shared antigens
IL279321A (en) Anti-sirpα antibody
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295B1 (en) Anti-pd-l1 antibodies
IL267797A (en) Anti-gpc3 antibody
IL280780A (en) Anti-tigit antibodies
SG10201603721TA (en) Anti-CTLA-4 Antibodies
IL279352A (en) Il-11ra antibodies
IL280013A (en) Anti-il36r antibodies
IL278010A (en) Galectin-10 antibodies
IL262776A (en) Humanized anti-il-1r3 antibodies
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
IL273529A (en) Anti-pacap antibody
IL281594A (en) Anti-klrg1 antibodies
GB201817172D0 (en) Antibody
GB201806084D0 (en) Antibodies
GB201511196D0 (en) Monoclonal antibodies
GB201819952D0 (en) Antibodies
GB201813597D0 (en) Antibody
GB201817312D0 (en) Antibodies
GB201817313D0 (en) Antibodies